Single Center Experience of Oral Vancomycin Therapy in Young Patients with Primary Sclerosing Cholangitis: A Case Series

There is no single proven therapy that prolongs hepatic transplant-free survival in patients with primary sclerosing cholangitis (PSC). Oral vancomycin (OV) has shown some benefit small pediatric and adult series. We describe the effect of OV on onset PSC at our tertiary hospital. This a single-center, retrospective, descriptive case series involving (<21 years diagnosis) from 2001 till 2021. The was assessed based symptoms, biochemical labs, imaging liver biopsy six twelve months, then annually until discontinued. inclusion criteria identified 17 patients. Baseline GGT (n = 17) elevated among 88.2% which normalized 53.8% 13) months 55.6% 9) one year post-OV. ALT 58.8% 42.8% 14) year. Imaging findings within revealed improved/stable biliary 66.7% 8/12). No adverse events were reported. associated an improvement bile duct injury marker (GGT) after least therapy, disease progression therapy.